Sangamo Bioscienes diskutieren
Sangamo Therapeutics Inc.
WKN: 936386 / Symbol: SGMO / Name: Sangamo Therapeutics / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
0,77 €
2,22 %
Buy Sangamo Bioscienes
Buy Sangamo Therapeutics Inc.
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $16.00 price target on the stock.
Ratings data for SGMO provided by MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its price target lowered by analysts at Wells Fargo & Company from $5.00 to $4.00. They now have an "overweight" rating on the stock.
Ratings data for SGMO provided by MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its price target lowered by analysts at Wedbush from $16.00 to $10.00. They now have an "outperform" rating on the stock.
Ratings data for SGMO provided by MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Ratings data for SGMO provided by MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its price target lowered by analysts at Truist Financial Co. from $8.00 to $7.00. They now have a "buy" rating on the stock.
Ratings data for SGMO provided by MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for SGMO provided by MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its price target lowered by analysts at HC Wainwright from $5.00 to $3.00. They now have a "buy" rating on the stock.
Ratings data for SGMO provided by MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for SGMO provided by MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for SGMO provided by MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for SGMO provided by MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for SGMO provided by MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for SGMO provided by MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for SGMO provided by MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for SGMO provided by MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Ratings data for SGMO provided by MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for SGMO provided by MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Ratings data for SGMO provided by MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Ratings data for SGMO provided by MarketBeat
Neueste Beiträge
StockNews_com in Cara Therapeutics Inc. diskutieren